A
Aspire Biopharma Holdings, Inc. (ASBP)
NCM – Real Time Price. Currency in USD
0.91
+0.00 (0.36%)
At close: Mar 27, 2026, 4:00 PM EDT
0.92
+0.01 (0.83%)
After-hours: Mar 27, 2026, 7:09 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
0.91
+0.00 (0.36%)
At close: Mar 27, 2026, 4:00 PM EDT
0.92
+0.01 (0.83%)
After-hours: Mar 27, 2026, 7:09 PM EDT
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
| Name | Position |
|---|---|
| Mr. Ernest J. Scheidemann Jr. | Chief Financial Officer |
| Mr. Kraig T. Higginson | Interim CEO, President & Executive Chairman of the Board |
| Mr. Stephen E. Quesenberry | General Counsel & Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-01-30 | 8-K | form8-k.htm |
| 2026-01-15 | 8-K | form8-k.htm |
| 2026-01-13 | 8-K | form8-k.htm |
| 2026-01-06 | 8-K | form8-k.htm |
| 2025-12-03 | S-1 | forms-1.htm |
| 2025-11-14 | 10-Q/A | form10-qa.htm |
| 2025-11-05 | 8-K | form8-k.htm |
| 2025-10-17 | 8-K | form8-k.htm |
| 2025-09-26 | CORRESP | filename1.htm |
| 2025-09-23 | DEF 14A | formdef14a.htm |